Related Experiment Video

Updated: Aug 20, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Lack of depression effect on platelet activation in patients with heart failure

Jagoda Pasic1, Mark D Sullivan, Joan Russo

  • 1Department of Psychiatry and Behavioral Sciences, University of Washington, Harborview Medical Center, 325 Ninth Avenue, Box 350896, Seattle, WA 98104-2499, USA. jpasic@u.washington.edu

Psychiatry Research
|January 22, 2005
PubMed

Insights

Comorbid depression does not increase platelet activation in congestive heart failure (CHF) patients. Soluble P-selectin levels, a marker of platelet activation, were similar in CHF patients with and without depression.

Area of Science:

  • Cardiology
  • Psychiatry
  • Hematology

Background:

  • P-selectin is a recognized marker of platelet activation.
  • Elevated P-selectin levels have been observed in patients with congestive heart failure (CHF) and depression as independent conditions.
  • The impact of comorbid depression on platelet activation in CHF patients remains unclear.

Purpose of the Study:

  • To investigate whether the presence of comorbid depression influences platelet activation in patients diagnosed with congestive heart failure.

Main Methods:

  • The study included 108 patients with congestive heart failure.
  • Twenty-four of these patients had comorbid depression.
  • Soluble P-selectin (sP-selectin) levels were measured in all participants.

Main Results:

  • No statistically significant differences were found in age or cardiac parameters between CHF patients with and without comorbid depression.
  • Soluble P-selectin levels did not differ significantly between the two groups.
  • These findings indicate no additive effect of comorbid depression on platelet activation in CHF patients.

Conclusions:

  • Comorbid depression does not appear to exacerbate platelet activation in patients with congestive heart failure.
  • Platelet activation markers, such as sP-selectin, do not show increased levels in CHF patients who also have depression.

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Related Concept Videos

G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...